Interventional equipment vendor C.R. Bard received 510(k) clearance this month from the Food and Drug Administration for its Memotherm Flexx biliary stent. The stent is used for treating malignant biliary obstructions, and will be marketed through Murray
Interventional equipment vendor C.R. Bard received 510(k) clearance this month from the Food and Drug Administration for its Memotherm Flexx biliary stent. The stent is used for treating malignant biliary obstructions, and will be marketed through Murray Hill, NJ-based Bards peripheral technologies division. The stent is available in diameters from 6 to 12 mm and lengths of 20 to 120 mm.
Can AI Predict Future Lung Cancer Risk from a Single CT Scan?
May 19th 2025In never-smokers, deep learning assessment of single baseline low-dose computed tomography (CT) scans demonstrated a 79 percent AUC for predicting lung cancer up to six years later, according to new research presented today at the American Thoracic Society (ATS) 2025 International Conference.
What if Radiology Turns Out Exactly the Way We Predict it Will?
May 19th 2025Whether it is reimbursement cuts or continued attempts to push non-radiologist image interpretation, where do we draw the line between inspired protest and misspent energy criticizing things that are doomed to fail or things we have no control over?
What a New PSMA PET/CT Study Reveals About Local PCa Treatment and High-Risk Recurrence
May 16th 2025For patients at high-risk for biochemical recurrence of prostate cancer, PSMA PET/CT findings revealed that 77 percent had one or more prostate lesions after undergoing local radiation therapy or radical prostatectomy, according to a recent study.